Adlaon, Kyle .
HRN: 26-25-86 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/19/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
11/19/2024
11/26/2024
IVTT
40mg
Q24h
T/C Neonatal Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes